96 related articles for article (PubMed ID: 16626317)
1. [A trip through the signaling pathways of melanoma].
Fensterle J
J Dtsch Dermatol Ges; 2006 Mar; 4(3):205-17. PubMed ID: 16626317
[TBL] [Abstract][Full Text] [Related]
2. [Genetic markers of melanoma].
Tronov VA; Artamonov DN; Gorbacheva LB
Genetika; 2010 Feb; 46(2):168-79. PubMed ID: 20297650
[TBL] [Abstract][Full Text] [Related]
3. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma.
Rothhammer T; Bosserhoff AK
Melanoma Res; 2006 Aug; 16(4):309-16. PubMed ID: 16845326
[TBL] [Abstract][Full Text] [Related]
4. A new piece in the melanoma mosaic--carcinosarcoma-like melanoma.
Svec A; Wilkinson L; Bury Y; Martin VG
Histopathology; 2009 Sep; 55(3):366-8. PubMed ID: 19723157
[No Abstract] [Full Text] [Related]
5. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Besch R; Berking C; Kammerbauer C; Degitz K
Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
7. Syntenin: a novel PDZ domain-containing scaffolding protein associated with human melanoma metastasis.
Yang JB; McCarthy JB
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):204-12. PubMed ID: 17478924
[TBL] [Abstract][Full Text] [Related]
8. Distribution of muscarinic receptor subtype M3 in melanomas and their metastases.
Oppitz M; Busch C; Garbe C; Drews U
J Cutan Pathol; 2008 Sep; 35(9):809-15. PubMed ID: 18422974
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of matrix metalloproteinases, chemokines, and chemokine receptors relevant for metastasis in experimental models not an indication of lymph node metastases in human melanoma.
Otto K; Starz H; Becker JC; Schrama D
Arch Dermatol; 2007 Jul; 143(7):947-8. PubMed ID: 17638747
[No Abstract] [Full Text] [Related]
10. Dipeptidyl peptidase II is not a marker for progression in melanoma.
Fröhlich E; Maier E; Mack AF; Garbe C
J Dermatol Sci; 2009 Jan; 53(1):68-71. PubMed ID: 18823758
[No Abstract] [Full Text] [Related]
11. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion.
Kääriäinen E; Nummela P; Soikkeli J; Yin M; Lukk M; Jahkola T; Virolainen S; Ora A; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2006 Oct; 210(2):181-91. PubMed ID: 16924594
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets?
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):383-6. PubMed ID: 20214982
[TBL] [Abstract][Full Text] [Related]
13. Identification of neoplastic cells in the lymphocytic infiltrate associated with thin melanomas.
Salvio AG; Ribeiro DA; Marques ME
Histopathology; 2007 Jun; 50(7):942-4. PubMed ID: 17543085
[No Abstract] [Full Text] [Related]
14. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the melanoma interactome.
Reed JA
J Cutan Pathol; 2008 Nov; 35 Suppl 2():11-5. PubMed ID: 18976413
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 3 expressed by melanoma cells as a target for therapy?
Salaun B; Lebecque S; Matikainen S; Rimoldi D; Romero P
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4565-74. PubMed ID: 17671143
[TBL] [Abstract][Full Text] [Related]
17. The inhibitor of apoptosis proteins as therapeutic targets in cancer.
Vucic D; Fairbrother WJ
Clin Cancer Res; 2007 Oct; 13(20):5995-6000. PubMed ID: 17947460
[TBL] [Abstract][Full Text] [Related]
18. Toxicogenomics of A375 human malignant melanoma cells treated with arbutin.
Cheng SL; Liu RH; Sheu JN; Chen ST; Sinchaikul S; Tsay GJ
J Biomed Sci; 2007 Jan; 14(1):87-105. PubMed ID: 17103032
[TBL] [Abstract][Full Text] [Related]
19. Targeting AKT signaling sensitizes cancer to cellular immunotherapy.
Hähnel PS; Thaler S; Antunes E; Huber C; Theobald M; Schuler M
Cancer Res; 2008 May; 68(10):3899-906. PubMed ID: 18483275
[TBL] [Abstract][Full Text] [Related]
20. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
